DBV Technologies reported $20.09M in Operating Expenses for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Operating Expenses Change
DBV Technologies DBVT:US USD 20.09M 5.26M
Acadia Pharmaceuticals ACAD:US USD 161.58M 6.63M
Alnylam Pharmaceuticals ALNY:US USD 598.93M 182.43M
Amarin AMRN:US USD 95.02M 62.25M
Biocryst Pharmaceuticals BCRX:US USD 93.27M 6.98M
Biomarin Pharmaceutical BMRN:US USD 507.76M 13.12M
Esperion Therapeutics ESPR:US USD 60.6M 10.61M
Galectin Therapeutics GALT:US USD 8.12M 1.54M
Halozyme Therapeutics HALO:US USD 128.4M 10.09M
Insmed INSM:US USD 195.43M 41.89M
Intercept Pharmaceuticals ICPT:US USD 179.49M 94.37M
IONIS PHARMACEUT IONS:US USD 218.92M 384K
Neurocrine Biosciences NBIX:US USD 300.1M 93.4M
Ptc Therapeutics PTCT:US USD 285.31M 27.43M
Sarepta Therapeutics SRPT:US USD 487.06M 42.45M
Ultragenyx Pharmaceutical RARE:US USD 315.77M 84.83M
United Therapeutics UTHR:US USD 201.7M 63.4M
YTE INCY:US USD 684.93M 27.96M